SEC Form 4 · accession 0001193125-26-390510
Amylyx Pharmaceuticals, Inc. · AMLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Camille L Bedrosian
Officer — Chief Medical Officer
Period of report
Sep 10, 2026
Accepted (ET)
Sep 14, 2026 · 4:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001658551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 10, 2026 | S | 7,947 | $32.2139 | D | 280,145 | D | |
| Common StockF3 | Sep 10, 2026 | S | 2,081 | $33.0919 | D | 278,064 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.76 to $32.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.85 to $33.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.